Our U.S. headquarters in Ridgefield, Conn. is home to one of Boehringer Ingelheim’s leading research and development sites with expertise across research, development and translational medicine and clinical pharmacology.
Our Human Pharma Research and Development Pipeline
With a pipeline of around 80 clinical and pre-clinical projects, and the potential to deliver up to 20 new medicine approvals in the next six years, we continue our track record of long-term innovation-led performance.
